Works matching IS 13419625 AND DT 2022 AND VI 27 AND IP 7


Results: 15
    1
    2
    3
    4
    5
    6
    7
    8
    9

    Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801.

    Published in:
    International Journal of Clinical Oncology, 2022, v. 27, n. 7, p. 1139, doi. 10.1007/s10147-022-02164-2
    By:
    • Hosokawa, Shinobu;
    • Ichihara, Eiki;
    • Harada, Daijiro;
    • Kuyama, Shoichi;
    • Inoue, Koji;
    • Gemba, Kenichi;
    • Ichikawa, Hirohisa;
    • Kato, Yuka;
    • Oda, Naohiro;
    • Oze, Isao;
    • Tamura, Tomoki;
    • Kozuki, Toshiyuki;
    • Umeno, Takahiro;
    • Kubo, Toshio;
    • Hotta, Katsuyuki;
    • Bessho, Akihiro;
    • Maeda, Yoshinobu;
    • Kiura, Katsuyuki
    Publication type:
    Article
    10

    Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study.

    Published in:
    International Journal of Clinical Oncology, 2022, v. 27, n. 7, p. 1154, doi. 10.1007/s10147-022-02162-4
    By:
    • Sakai, Daisuke;
    • Omori, Takeshi;
    • Fumita, Soichi;
    • Fujita, Junya;
    • Kawabata, Ryohei;
    • Matsuyama, Jin;
    • Yasui, Hisateru;
    • Hirao, Motohiro;
    • Kawase, Tomono;
    • Kishi, Kentaro;
    • Taniguchi, Yoshiki;
    • Miyazaki, Yasuhiro;
    • Kawada, Junji;
    • Satake, Hironaga;
    • Miura, Tomoko;
    • Miyake, Akimitsu;
    • Kurokawa, Yukinori;
    • Yamasaki, Makoto;
    • Yamada, Tomomi;
    • Satoh, Taroh
    Publication type:
    Article
    11
    12
    13
    14
    15